08 January,2021 06:11 PM IST | London | IANS
Nurse Laura Bailey draws the Moderna vaccine from the first batch of Moderna`s vaccine at Hartford hospital in Hartford, Connecticut on December 21, 2020. Pic/AFP
The UK's regulatory authority on Friday approved a third COVID-19 vaccine for use in the country, made by the company Moderna.
However, supplies of the new jab are not expected to be available until the spring in a few weeks' time as the UK has pre-ordered 7 million doses. In trials with more than 30,000, the Moderna vaccine offered nearly 95 per cent protection from severe COVID.
The Moderna vaccine works in a similar way to the Pfizer/BioNTech vaccine that is already being offered by the National Health Service (NHS). It requires temperatures of around -20C for shipping -- similar to a normal freezer. In comparison, the Pfizer/BioNTech one requires temperatures closer to -75C, making transport logistics much more difficult.
The Oxford/AstraZeneca jab is easier to store and distribute, as it can be kept at normal fridge temperature.
ALSO READ
Let’s not panic, but work on containing HMPV
No comparison between COVID 19 and HMPV, says expert
HMPV outbreak: Maharashtra steps up alert for medical colleges and hospitals
'HMPV isn't new, majority Indian population immune to it,' say experts
Bengaluru: Case registered in connection with COVID-19 mismanagement
All three vaccines, now cleared for use in the UK, require a second booster shot.
Around 1.5 million people in the UK have had at least one dose of COVID-19 vaccine so far, the Pfizer/BioNTech and Oxford/AstraZeneca jabs.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
